

Olainfarm –
Your Path To Pharmaceutical Excellence



**Your health is
our passion!**

www.olainfarm.com

One of the Leading Pharmaceutical companies in the Baltic Region with 50+ years of industry experience

Diverse Product Portfolio:

60 finished dosage forms, 19 active pharmaceutical substances, and 14 intermediates, covering essential therapeutic areas. Product portfolio is continuously developed and expanded.

Advantages of Choosing Olainfarm:

- **Reliable Supply Chains:** we ensure consistent product availability to meet market demand.
- **Cost Efficiency:** advantages from lower labor costs, efficient production processes and regionally developed logistics.
- **High-Quality Standards:** Adherence to the highest industry quality and safety standards.
- **Sustainability:** Recognized for sustainability efforts, including a solar panel park to provide 40% of our energy by 2024.

Future Plans:

At least 100 million euros investment for 5 years to drive innovation and sustainability.

Commitment to Success:


Choose Olainfarm for a financially stable out-licensing partner with extensive therapeutic expertise and a focus on building long-term, successful relationships.

Olainfarm is a part of the AB City group

2nd most valuable local private capital holding in Latvia (748 mn. EUR in 2021)

Holding includes Baltic market leaders in healthcare providers, wholesale, manufacturing, laboratory examination services, and pharmacy chains etc.

* Figures provided are for December 2022, unless stated otherwise



Olainfarm Group: Network of Pharmaceutical Excellence





OUR BUSINESS GOAL

To become one of the
TOP 10 pharmaceutical
companies in Europe in its
therapeutical areas



OUR MISSION

To support and help our
patients in all stages of
healthcare


Olainfarm in key facts & figures




120,25 mn EUR
neto consolidated turnover,
2022



840 professional employees
in Olainfarm and more than 1400
employees in the Olainfarm group



> 1 billion
production capacity for tablets
and capsules per year



48 ha
area of the company
in Olaine



8,1 mn EUR
investment in R&D,
2022



Golden Award
National Sustainability Index,
2023

Experienced and professional management team



Juris Bundulis

Chairman of the Board

Juris brings decades of experience in leading major pharmaceutical companies in the Baltics and has a distinguished background in high-level government administration. He joined Olainfarm in 2021 as the Chairman of the Supervisory Board, and since September 2022, he has held the position of Chairman of the Board. Prior to that, he held prominent positions in other healthcare companies and possesses extensive experience in public administration. Juris has doctoral degrees in both chemistry and biology.



Jānis Leimanis

Board Member, CFO


Jānis is a finance professional with extensive experience in business and finance. He has been a board member of Olainfarm since June 2021, overseeing financial matters. Previously Jānis has worked in asset management, financial services, and leadership roles in both public and private sectors. He holds a bachelor's degree in mechanics, engineer degree in economics, Mini MBA and ACCA.



Andris Jegorovs

Board Member, CPO

Andris is a pharmaceutical professional with over 35 years of experience. He has been a board member of Olainfarm since September 2022 and has been the Production Director since 2021. Andris holds degrees in chemical technology and an MBA, and he is an industry expert with significant contributions to the Latvian Chemical and Pharmaceutical Industry Association (LAKIFA) and other NGOs.



Raimonds Terentjeps

Director of Quality Management Department

Raimonds has over 25 years of experience in the chemical and pharmaceutical sectors. Having previously worked as a researcher at the Latvian Institute of Organic Synthesis, he joined Olainfarm in 2011 as the head of the R&D laboratory and since 2016 he serves as the Director of Quality Management. Raimonds holds master's degree in chemistry.



Elena Bushberg

Executive Director


Elena has over 25 years of experience in international pharmaceutical companies, including "Schering-Plough," "MSD," and "Abbott Laboratories." Her skills include strategy development, leading transformation, and fostering a culture of efficiency. She holds a Global Executive MBA from Duke University – The Fuqua School of Business. Since 2020, she has served as the Executive Director at Olainfarm



Ēriks Ivanovskis

Director of Scientific Office

Ēriks is a seasoned professional with over 25 years of experience in pharmaceutical development, including leadership roles in FDF and API development, regulatory and medical affairs, and contract research and development. He holds a Master's degree in Pharmacy and a Master's degree in Chemistry. Currently serving as the Scientific Office Director at Olainfarm since September 2022.



Viktorija Zefirova-Tačinska

Change and Development Process Manager

Viktorija brings extensive production and healthcare management experience, spanning international and Latvian firms and the public sector. With expertise in change management and corporate culture transformation, she holds an MBA from Riga Technical University and a cardiology specialization from Rīga Stradiņš University. She joined Olainfarm management team in 2022.



Vladimirs Krušinskis

Director of Technical Department

Vladimirs, with over 20 years of experience in manufacturing companies, currently serves as the Director of the Technical Department at Olainfarm. He joined the company in 2012, previously working at AS "Rīgas Farmacitiskā fabrika." Vladimirs holds a bachelor's degree in engineering.



Key pillars of Olainfarm: Research, manufacturing, distribution



DISTRIBUTION

- Pharmacies & chains of pharmacies
- Partners & distributors

RESEARCH

- Development of new active pharmaceutical ingredients and final dosage forms
- Registration affairs
- Clinical studies and medical affairs



MANUFACTURING

- Active pharmaceutical ingredients & intermediates
- Finished dosage forms: tablets, capsules, powder in sachets



Patient health

Development of product portfolio in all key healthcare areas



~ 60
stock keeping units



19
active pharmaceutical
ingredients



14
intermediates



~50
new products under development to
expand product portfolio:

- finished dosage forms in key therapeutic areas
- active pharmaceutical ingredients

Olainfarm is Qualified Supplier of Anti-Tuberculosis Medicines to the World Health Organization


* Figures provided are for December 2022, unless stated otherwise

Main therapeutical areas

Existing
therapeutical
areas




Nervous System



Antibacterial
agents




Cardiology




Antiallergens


New
therapeutical
areas



Anti-Diabetic



Urology



Oncology

Portfolio for out-licensing

Sr No	Product Name	Pilot BE	Dossier Readiness
1	Rivaroxaban Tabs	Pivotal BE successful	Nov-23 (DCP slot available in Dec-23)
2	Dapagliflozin + Metformin Tabs	Successful	Q3 2024
3	Melatonin 2mg PR Tabs	Q2 2024	Q1 2025
4	Dapagliflozin Tabs	Q3 2024	Q2 2025
5	Empagliflozin Tabs	Q3 2024	Q2 2025
6	Melatonin 1 mg and 5mg PR Tabs	Q4 2024	Q2 2025
7	Enzalutamide Tabs	Q4 2024	Q3 2025
8	Palbociclib Tabs	Q4 2024	Q3 2025
9	Ibrutinib Tabs	Q4 2024	Q3 2025
10	Cabozantinib Tabs	Q4 2024	Q3 2025
11	Olaparib Tabs	Q2 2025	Q4 2026


Export to

60+

countries worldwide



OlainFarm



Quality Assurance and Certifications

EU GMP: Compliant for APIs and FDFs

U.S. FDA GMP: Certified for selected APIs

Australian TDA: Certified for FDFs

Turkey GMP: Certified for FDFs

Japanese PMDA GMP: Certified for selected APIs

ISO 14001:2015: Environmental responsibility

ISO/IEC 17025:2017: Laboratory excellence

WHO Qualified: Anti-tuberculosis meds supplier



More than 100 million EUR allocated to the development projects




Product Portfolio
Development & Expansion
in New Export Markets



Reconstruction of
Wastewater Treatment
Systems



Production Modernization,
Automation, and Capacity
Enhancement



Green Energy,
Energy Efficiency
and Sustainability



Digitalization



Employee Well-being, and
Further Improvements of
Working Conditions

Olainfarm's Contribution to the ESG Principles

E Environmental

28.6% Reduction in Carbon Emissions Over the Past 5 Years.

Implementation of Renewable Energy Sources, Including a 3.2 MWh Solar Panel Park.

Renovation of existing external heating and steam pipelines to reduce carbon emissions (heat losses).

Our target is to invest at least 3 million EUR yearly in environmental and energy efficiency projects until 2027.

New Wastewater Treatment System for Sustainable Water Management.

ISO 14001:2015 Certification for Environmental Responsibility and its supplementation by a continuous energy consumption evaluation process.

S Social

Active Engagement in Local Communities, Supporting Education, Healthcare, and Science

Employee Well-being Programs, Including Mental Health Support

A Diverse and Inclusive Workforce with 56% Female Representation Among Unit Managers

High Focus on Workplace Safety

G Governance

Transparent Corporate Governance Practices and Reporting

Strong Ethical Business Standards, Including Anti-Corruption and AML Measures

A Board of Directors Comprising Industry Experts and Thought Leaders

Full Compliance with Regulatory Standards and Regular Audits



Golden Award in the National Sustainability Index for Two Consecutive Years (2022 and 2023)

Taking care of your health for more than 50 years



www.olainfarm.lv

bdd@olainfarm.com

Rūpnīcu iela 5, Olaine, Latvia

www.olainfarm.com